Tampere University of Technology

TUTCRIS Research Portal

Sarcopenia during androgen-deprivation therapy for prostate cancer

Research output: Contribution to journalArticleScientificpeer-review

Standard

Sarcopenia during androgen-deprivation therapy for prostate cancer. / Smith, Matthew R.; Saad, Fred; Egerdie, Blair; Sieber, Paul R.; Tammela, Teuvo L J; Ke, Chunlei; Leder, Benjamin Z.; Goessl, Carsten.

In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 30, No. 26, 10.09.2012, p. 3271-3276.

Research output: Contribution to journalArticleScientificpeer-review

Harvard

Smith, MR, Saad, F, Egerdie, B, Sieber, PR, Tammela, TLJ, Ke, C, Leder, BZ & Goessl, C 2012, 'Sarcopenia during androgen-deprivation therapy for prostate cancer', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 30, no. 26, pp. 3271-3276. https://doi.org/10.1200/JCO.2011.38.8850

APA

Smith, M. R., Saad, F., Egerdie, B., Sieber, P. R., Tammela, T. L. J., Ke, C., ... Goessl, C. (2012). Sarcopenia during androgen-deprivation therapy for prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(26), 3271-3276. https://doi.org/10.1200/JCO.2011.38.8850

Vancouver

Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Sep 10;30(26):3271-3276. https://doi.org/10.1200/JCO.2011.38.8850

Author

Smith, Matthew R. ; Saad, Fred ; Egerdie, Blair ; Sieber, Paul R. ; Tammela, Teuvo L J ; Ke, Chunlei ; Leder, Benjamin Z. ; Goessl, Carsten. / Sarcopenia during androgen-deprivation therapy for prostate cancer. In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 ; Vol. 30, No. 26. pp. 3271-3276.

Bibtex - Download

@article{1caad6bfa6e9471a9c0e57c96ee3bcaf,
title = "Sarcopenia during androgen-deprivation therapy for prostate cancer",
abstract = "Purpose: To characterize changes in lean body mass (LBM) in men with prostate cancer receiving androgen-deprivation therapy (ADT). Patients and Methods: We prospectively evaluated LBM in a prespecified substudy of a randomized controlled trial of denosumab to prevent fractures in men receiving ADT for nonmetastatic prostate cancer. LBM was measured by total-body dual-energy x-ray absorptiometry at study baseline and at 12, 24, and 36 months. The analyses included 252 patients (132, denosumab; 120, placebo) with a baseline and at least one on-study LBM assessment. Patients were stratified by age (<70 v ≥ 70 years) and by ADT duration (≤ 6 v > 6 months). Results: Median ADT duration was 20.4 months at study baseline. Mean LBM decreased significantly from baseline, by 1.0{\%} at month 12 (95{\%} CI, 0.4{\%} to 1.5{\%}; P <.001; n = 248), by 2.1{\%} at month 24 (95{\%} CI, 1.5{\%} to 2.7{\%}; P <.001; n = 205), and by 2.4{\%} at month 36 (95{\%} CI, 1.6{\%} to 3.2{\%}; P <.001; n = 168). Men age ≥ 70 years (n = 127) had significantly greater changes in LBM at all measured time points than younger men. At 36 months, LBM decreased by 2.8{\%} in men age ≥ 70 years and by 0.9{\%} in younger men (P = .035). Men with ≤ 6 months of ADT at study entry (n = 36) had a greater rate of decrease in LBM compared with men who had received more than 6 months of ADT at study entry (3.7{\%} v 2.0{\%}; P = .0645). Conclusion: In men receiving ADT, LBM decreased significantly after 12, 24, and 36 months.",
author = "Smith, {Matthew R.} and Fred Saad and Blair Egerdie and Sieber, {Paul R.} and Tammela, {Teuvo L J} and Chunlei Ke and Leder, {Benjamin Z.} and Carsten Goessl",
year = "2012",
month = "9",
day = "10",
doi = "10.1200/JCO.2011.38.8850",
language = "English",
volume = "30",
pages = "3271--3276",
journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "26",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Sarcopenia during androgen-deprivation therapy for prostate cancer

AU - Smith, Matthew R.

AU - Saad, Fred

AU - Egerdie, Blair

AU - Sieber, Paul R.

AU - Tammela, Teuvo L J

AU - Ke, Chunlei

AU - Leder, Benjamin Z.

AU - Goessl, Carsten

PY - 2012/9/10

Y1 - 2012/9/10

N2 - Purpose: To characterize changes in lean body mass (LBM) in men with prostate cancer receiving androgen-deprivation therapy (ADT). Patients and Methods: We prospectively evaluated LBM in a prespecified substudy of a randomized controlled trial of denosumab to prevent fractures in men receiving ADT for nonmetastatic prostate cancer. LBM was measured by total-body dual-energy x-ray absorptiometry at study baseline and at 12, 24, and 36 months. The analyses included 252 patients (132, denosumab; 120, placebo) with a baseline and at least one on-study LBM assessment. Patients were stratified by age (<70 v ≥ 70 years) and by ADT duration (≤ 6 v > 6 months). Results: Median ADT duration was 20.4 months at study baseline. Mean LBM decreased significantly from baseline, by 1.0% at month 12 (95% CI, 0.4% to 1.5%; P <.001; n = 248), by 2.1% at month 24 (95% CI, 1.5% to 2.7%; P <.001; n = 205), and by 2.4% at month 36 (95% CI, 1.6% to 3.2%; P <.001; n = 168). Men age ≥ 70 years (n = 127) had significantly greater changes in LBM at all measured time points than younger men. At 36 months, LBM decreased by 2.8% in men age ≥ 70 years and by 0.9% in younger men (P = .035). Men with ≤ 6 months of ADT at study entry (n = 36) had a greater rate of decrease in LBM compared with men who had received more than 6 months of ADT at study entry (3.7% v 2.0%; P = .0645). Conclusion: In men receiving ADT, LBM decreased significantly after 12, 24, and 36 months.

AB - Purpose: To characterize changes in lean body mass (LBM) in men with prostate cancer receiving androgen-deprivation therapy (ADT). Patients and Methods: We prospectively evaluated LBM in a prespecified substudy of a randomized controlled trial of denosumab to prevent fractures in men receiving ADT for nonmetastatic prostate cancer. LBM was measured by total-body dual-energy x-ray absorptiometry at study baseline and at 12, 24, and 36 months. The analyses included 252 patients (132, denosumab; 120, placebo) with a baseline and at least one on-study LBM assessment. Patients were stratified by age (<70 v ≥ 70 years) and by ADT duration (≤ 6 v > 6 months). Results: Median ADT duration was 20.4 months at study baseline. Mean LBM decreased significantly from baseline, by 1.0% at month 12 (95% CI, 0.4% to 1.5%; P <.001; n = 248), by 2.1% at month 24 (95% CI, 1.5% to 2.7%; P <.001; n = 205), and by 2.4% at month 36 (95% CI, 1.6% to 3.2%; P <.001; n = 168). Men age ≥ 70 years (n = 127) had significantly greater changes in LBM at all measured time points than younger men. At 36 months, LBM decreased by 2.8% in men age ≥ 70 years and by 0.9% in younger men (P = .035). Men with ≤ 6 months of ADT at study entry (n = 36) had a greater rate of decrease in LBM compared with men who had received more than 6 months of ADT at study entry (3.7% v 2.0%; P = .0645). Conclusion: In men receiving ADT, LBM decreased significantly after 12, 24, and 36 months.

UR - http://www.scopus.com/inward/record.url?scp=84866595620&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.38.8850

DO - 10.1200/JCO.2011.38.8850

M3 - Article

VL - 30

SP - 3271

EP - 3276

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

SN - 0732-183X

IS - 26

ER -